Navigation Links
Resverlogix's Success in Inflammation Program Results in 2 Patents Filed

    Novel small molecules illustrate potential cost effective approach for
    rheumatoid arthritis

    TSX Exchange Symbol: RVX

CALGARY and ATLANTA, May 19 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today that it has made significant advancement in the Company's research and development (R&D) program for inflammatory diseases. Two new patent applications have been filed for novel compounds and their use in regulating inflammatory markers. Inflammatory markers are proteins generated by the body during periods of inflammation. These patents were filed based on the successful results demonstrated in numerous preclinical studies across several disease areas. The particular results achieved in the collagen induced arthritis (CIA) model in rats demonstrated that Resverlogix's proprietary molecules markedly reduced inflammation while improving mobility of arthritic animals.

"Resverlogix's R&D program has made significant strides this past year," said Donald J. McCaffrey, President & CEO of Resverlogix. "The Company has identified several molecules that have the potential for disease modifying effects in inflammatory disorders such as rheumatoid arthritis. Resverlogix's R&D team is continuing to examine the various disease indications in inflammation which would have the greatest potential impact for both patients and payer groups," continued McCaffrey.

A significant unmet medical need exists for safe, effective and economical therapies for specific inflammation markets. For example, a small molecular drug for rheumatoid arthritis is estimated to range in price from US $180 - US $6000 per person per annum. A biologic, or large molecule drug, can cost in the order of US $13,000 - US $30,000 per patient per annum. In 2007, the global market for rheumatoid arthritis alone was estimated to be in excess of US $11 billion a year and is expected to grow to US $27 billion by the year 2015. These important markets require novel therapies to reduce pain and symptoms in a cost efficient manner. Resverlogix's novel small molecules have the illustrated early potential to fill this important gap.

Kenneth Lebioda, Senior Vice President of Business & Corporate Development of Resverlogix stated, "The inflammation market is enormous with many significant unmet needs. Current leading therapeutics such as biologics are effective, but also very expensive. Resverlogix's platform technology has created novel small molecules which illustrate potent anti-inflammatory effects in arthritis models as compared with leading biologic agents." Lebioda highlighted, "The early efficacy data from these compounds is exciting for the reason that small molecules would offer significant cost savings to health systems over current biologic agents."

Inflammation is a normal response of the body to protect tissues from infection, injury or disease. Though it promotes healing, if uncontrolled, the inflammatory response may become harmful. Acute or chronic inflammation is known to play a key role in diverse disease states, such as atherosclerosis and rheumatoid arthritis. Worldwide it is estimated that more than 80 million people suffer from inflammatory diseases.

Resverlogix will be presenting at the BIO Business Forum held at the Convention Center in Atlanta, Georgia on Wednesday, May 20, 2009 at 9:20 am EDT in Room 313.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
2. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
3. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
4. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
5. VeraSun Energy Selects Valero as Successful Bidder for Seven Facilities
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
8. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
9. Addiction Treatment Finds Success Treating Brain Deficiencies through the Belly
10. Avid Bioservices Presents Data From Manufacturing Successes Achieved With Single-Use Bioreactor Systems
11. Sundia MediTech and Xcovery Announce Big Success in Drug Discovery
Post Your Comments:
(Date:10/13/2015)... Applied BioMath ( ), a computational ... the drug invention process, announced that it will sponsor ... 20-22, 2015 in Boston , MA.  ... CEO of Applied BioMath, will present "QSP approaches enabling quantitative ... trials" on Wednesday October 21st 2015 at 12:30PM.  ...
(Date:10/13/2015)... --      Q BioMed Inc (OTC: QBIO), ... a strategic relationship with Wombat Capital, Ltd., a ... France based strategic and scientific advisory firm.. ... collaborative arrangement gives Q BioMed and its stakeholders access ... as long established pharmaceutical industry relationships. The advisors within ...
(Date:10/13/2015)... ... 2015 , ... Clinovo recently appointed Jeff Parr and Ed Donaldson to its ... solutions business. , Jeff Parr has spent the past decade providing quality management software ... Fisher, and Ab Sciex to name a few. He is based in Salt ...
(Date:10/12/2015)... , Oct. 12, 2015  Amgen (NASDAQ: AMGN ... from an exploratory sub-study of the previously reported romosozumab Phase ... an oral plenary session at the American Society for Bone ... Seattle . 2 --> ... sub-study data showed that, at month 12, the investigational bone-forming ...
Breaking Biology Technology:
(Date:10/5/2015)... , October 5, 2015 ... company update for NXT-ID, Inc. (NASDAQ: NXTD ), ... commerce market. --> ) ... Inc. (NASDAQ: NXTD ), a biometric authentication company ... SoundView Technology Group ( ) ...
(Date:9/30/2015)... global glucose monitoring device and diabetes management market is valued ... on the industry from Kalorama Information. Sales in the traditional glucose ... continuous glucose monitoring and sensor segment, according to the healthcare ... in its latest report, The Global Glucose Monitoring Market ... , ...
(Date:9/28/2015)... SAN FRANCISCO , September 28, 2015 ... size is expected to reach USD 12.03 billion by ... to 2020. Technological advancements such as Backside Illumination (BSI) ... revenue growth over the forecast period.      ... the back of the chip to reduce loss and, ...
Breaking Biology News(10 mins):